Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 20/20 | 0.73 |
| ▸ | TACR2 | P21452 | 8/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | TACR1 | P25103 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | ATM | Q13315 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581130 | 1.00 | TACR3 (0.73) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1582032 | 0.91 | TACR3 (0.72) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1580927 | 0.91 | TACR3 (0.67) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8194198 | 0.91 | TACR3 (0.67) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1581625 | 0.88 | TACR3 (0.57) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8192454 | 0.88 | TACR3 (0.57) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1580940 | 0.87 | TACR3 (0.78) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1581178 | 0.87 | TACR3 (0.78) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3322299 | 0.86 | TACR3 (0.53) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1581125 | 0.86 | TACR3 (0.53) | TACR3TACR2CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214605-A1 | Alkyl Sulfoxide Quinolines as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | claimed |
| US-20160220555-A1 | Method For Treating Or Preventing Hot Flushes | IMPERIAL WHITE CITY INCUBATOR LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160220555-A1 | Method For Treating Or Preventing Hot Flushes | IMPERIAL WHITE CITY INCUBATOR LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-7964733-B2 | to potentiate the effects of the other CNS agents; probes for the localization of cell surface receptors;3-(methylthio)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide; depression, anxiety, schizophrenia, cognitive disorders, obesity, irritable bowel syndrome, emesis, pre-eclampsia, etc. | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-7964733-B2 | to potentiate the effects of the other CNS agents; probes for the localization of cell surface receptors;3-(methylthio)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide; depression, anxiety, schizophrenia, cognitive disorders, obesity, irritable bowel syndrome, emesis, pre-eclampsia, etc. | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-7964733-B2 | to potentiate the effects of the other CNS agents; probes for the localization of cell surface receptors;3-(methylthio)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide; depression, anxiety, schizophrenia, cognitive disorders, obesity, irritable bowel syndrome, emesis, pre-eclampsia, etc. | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| EP-1928835-B1 | ALKYL SULFOXIDE QUINOLINES AS NK-3 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| US-20100120850-A1 | Quinoline Derivatives, Pharmaceutical Compositions Comprising Them, and Their Use in Treating Central Nervous System and Peripheral Diseases | ASTRAZENECA AB (SE) | 2010-05-13 | — | — | US | disclosed |
| US-20100120850-A1 | Quinoline Derivatives, Pharmaceutical Compositions Comprising Them, and Their Use in Treating Central Nervous System and Peripheral Diseases | ASTRAZENECA AB (SE) | 2010-05-13 | — | — | US | disclosed |
| US-20100120850-A1 | Quinoline Derivatives, Pharmaceutical Compositions Comprising Them, and Their Use in Treating Central Nervous System and Peripheral Diseases | ASTRAZENECA AB (SE) | 2010-05-13 | — | — | US | disclosed |
| WO-2008115140-A1 | QUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THEIR USE IN TREATING CENTRAL NERVOUS SYSTEM AND PERIPHERAL DISEASES | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | WO | disclosed |
| US-20080214605-A1 | Alkyl Sulfoxide Quinolines as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214605-A1 | Alkyl Sulfoxide Quinolines as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214605-A1 | Alkyl Sulfoxide Quinolines as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| WO-2007035158-A1 | ALKYL SULFOXIDE QUINOLINES AS NK-3 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120850-A1 | Quinoline Derivatives, Pharmaceutical Compositions Comprising Them, and Their Use in Treating Central Nervous System and Peripheral Diseases | PMP22, RECQL, ACHE | TACR3 531/4885TACR2 1434/4885CYP1A2 75/4885 |
| US-20160220555-A1 | Method For Treating Or Preventing Hot Flushes | KLK5, KISS1R, KLKB1 | TACR3 7/4885TACR2 10/4885CYP1A2 1561/4885 |
| US-20080214605-A1 | Alkyl Sulfoxide Quinolines as Nk-3 Receptor Ligands | MSR1, KCNQ3, KCNA3 | TACR3 13/4885TACR2 6/4885CYP1A2 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.